Ocugen (OCGN) EBITDA (2014 - 2026)

Ocugen has reported EBITDA for 13 years, with the latest figure at -$19.3 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 25.54% year-over-year to -$19.3 million; the trailing twelve-month figure through Mar 2026 stood at -$71.8 million (down 24.87% YoY), and the FY2025 full-year result was -$67.8 million, down 25.56% from the prior year.
• EBITDA for Q1 2026 stood at -$19.3 million, down from -$17.7 million in the prior quarter.
• The five-year high for EBITDA was -$11.0 million in Q4 2023, with the low at -$23.9 million in Q3 2022.
• Historically, EBITDA has averaged -$17.1 million across 5 years, with a median of -$17.3 million in 2023.
• Annual changes were most pronounced in 2022 — EBITDA sank 168.69% — and 2023, when it soared 50.99%.
• Ocugen's EBITDA stood at -$22.4 million in 2022, then soared by 50.99% to -$11.0 million in 2023, then slipped by 26.22% to -$13.9 million in 2024, then declined by 27.77% to -$17.7 million in 2025, then declined by 8.91% to -$19.3 million in 2026.
• The last three EBITDA figures came in at -$19.3 million (Q1 2026), -$17.7 million (Q4 2025), and -$20.0 million (Q3 2025), per Business Quant data.